MKI67 and cancer: While no cancer records exist to date in Mexico at the national, regional, nor state levels, great efforts have been made within the program for screening and co-testing for CC in the ISSSTE to integrate such screening with an comprehensive care model with a process-oriented approach, going from the traditional cytology-only scheme to a combination of cytology and HR-HPV genotyping, aiming to implement liquid-based cytology in the future, along with HR-HPV genotyping and immunohistochemical tests (p16, ki67).